AR and cancer: Proteolysis‐targeting chimera (PROTAC) drug design strategy provides a new opportunity for cancer therapeutic development involving the induction of protein degradation.[23] A PROTAC drug is a heterobifunctional molecule containing one ligand that binds to the target protein of interest and a second ligand for an E3 ligase.[24] As the AR protein plays a key role in CRPC, several small‐molecule PROTAC drugs target the full‐length AR, including ARV‐110,[25] ARCC‐4,[26] and ARD‐69,[27] have achieved great efficacy.